XML 21 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Statements of Cash Flows - USD ($)
12 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Operating Activities:    
Net loss $ (3,745,042) $ (876,754)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:    
Depreciation and amortization 483,087 153,283
Provision for doubtful accounts 150,000
Warranty provision 6,093 (70,946)
Inventory obsolescence 171,535 26,243
Share-based compensation 584,873 1,116,400
Deferred income taxes 2,374,000 196,000
Gain on disposition of fixed asset 252
Loss on impairment of patents 11,133
Changes in operating assets and liabilities:    
Accounts receivable, net 3,149,579 (2,272,970)
Inventories, net (1,648,484) (519,568)
Prepaid expenses and other (2,075,323) (147,456)
Other assets (60,615) 226,937
Accounts payable 192,638 537,800
Payroll and related 127,623 1,487,734
Warranty settlements (11,395) (67,959)
Accrued and other liabilities 1,541,865 (455,516)
Net cash provided by (used in) operating activities 1,251,819 (666,772)
Investing Activities:    
Purchases of marketable securities (4,920,547) (2,908,093)
Proceeds from maturities of marketable securities 5,190,821 2,961,367
Capital expenditures (625,845) (182,326)
Purchase of Genasys, net of cash and restricted cash acquired (2,431,795)
Net cash used in investing activities (2,787,366) (129,052)
Financing Activities:    
Proceeds from exercise of stock options 2,434,888 133,000
Repurchase of common stock (725,445)
Proceeds from the issuance of unsecured promissory notes 62,656
Payments on promissory notes (1,175,205)
Net cash provided by financing activities 596,894 133,000
Effect of foreign exchange rate on cash (59,160)
Net decrease in cash, cash equivalents, and restricted cash (997,813) (662,824)
Cash, cash equivalents and restricted cash, beginning of period 12,803,887 13,466,711
Cash, cash equivalents and restricted cash, end of period 11,806,074 12,803,887
Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets:    
Cash and cash equivalents 11,063,091 12,764,421
Restricted cash, current portion 403,427
Long-term restricted cash 339,556 39,466
Supplemental disclosures of cash flow information:    
Interest paid 18,015
Noncash investing and financing activities:    
Change in unrealized loss on marketable securities (7,676) 280
Business combinations accounted for as a purchase:    
Fair value of assets acquired 5,520,504
Cash paid (3,011,439)
Liabilities assumed $ 2,509,065